Search
Summit Therapeutics Inc
SMMTAdd to Watchlist
15.420USD
+1.040+7.23%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
11.97BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Summit Therapeutics Inc is 7.22, ranking 307 out of 387 in the Biotechnology & Medical Research industry. The average price target is 34.50, with a high of 42.00 and a low of 12.00.
Analyst Rating
Based on
18
analysts
Buy
Current Rating
30.369
Target Price
+111.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Summit Therapeutics Inc
SMMT
18
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Summit Therapeutics Inc's price target?
Analysts forecast that Summit Therapeutics Inc's price target is USD 34.50, with the highest forecast at USD 42.00 and the lowest forecast at USD 12.00.
How have Summit Therapeutics IncSMMT's recent earnings per share performed?
The market expectation was USD -0.24, while Summit Therapeutics IncSMMT's earnings per share (EPS) for the previous quarter was USD -1.44. EPS for the next quarter is expected at USD -0.28.
What is the analyst rating for Summit Therapeutics Inc?
Based on the ratings of Summit Therapeutics Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.